A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of COPD Drugs Market. The report analyses the COPD Drugs Market By Drug Type (Combination Therapy Drugs, Anticholinergics, Beta-Agonist, Inhaled Corticosteroids, andOthers). The report analyses the COPD Drugs Market, By Region (North America, Europe, Asia Pacific, Rest of the World) and By Country (U.S., Canada, Germany, U.K, France, Italy, China, Japan, India) for the historical period of 2013-2017 and the forecast period of 2018-2023. This report also includes pipeline analysis for few COPD drugs. Request free Sample of this Report @ http://azothanalytics.com/report/healthcare-pharma/global-copd-drugs-market-analysis-by-drug-type-combination-therapy-anticholinergics-beta-agonist-inhaled-corticosteroids-others-pipeline-drugs-by-region-by-country-2019-edition-forecast-to-2023-r29194 COPD Drugs Market Analysis Visit us: http://azothanalytics.com/research/healthcare-pharma-c1

1. (c) AZOTH Analytics
• By Region – North America, Europe, APAC,
ROW.
• By Country - US, Canada, UK, Germany, France,
Italy, China, Japan, India, Rest of the world.
• Pipeline Analysis: PT010, Duaklir, Nemiralisib,
Danirixin.
• Product Analysis.
February 2019
Global COPD Drugs Market: Analysis By Drug Type
(Combination Therapy Drugs, Anticholinergics, Beta-
Agonist, Inhaled Corticosteroids, Others), Pipeline Drugs, By
Region, By Country (2019 Edition): Forecast to 2023

2. (c) AZOTH Analytics
Scope of the Report – COPD Drugs Market
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Global
Market (By Value)
By Drugs Type,
By Value
Combination
Therapy           
Anticholiner
gics           
Beta-
Agonist           
ICS           
Others           
Regional
By Drugs Type,
By Value
Combination
Therapy           
Anticholiner
gics           
Beta-
Agonist           
ICS           
Others           
Country
By Drugs Type,
By Value
Combination
Therapy           
Anticholiner
gics           
Beta-
Agonist           
ICS           
Others           
By Company
Glaxo SmithKline, AstraZeneca, Boehringer-Ingelheim, TEVA Pharmaceuticals, Chiesi Pharmaceuticals, Novartis, Merck, Cipla, Mylan, Vectura,
and Sunovion.
By Region North America, Europe, APAC, and ROW.
By Country US, Canada, UK, Germany, France, Italy, China, Japan, India, Rest of the world.
Historical Forecast
2

3. (c) AZOTH Analytics
Table of Content
S.No Particulars Page No.
1. Research Methodology 26
2. Executive Summary 27
3. Strategic Recommendation 28
3.1 Invest in COPD Generic Drugs 29
3.2 Asia Pacific Region To Witness The Fastest Growth 30
4. COPD Drugs Products Outlook 31
5. Global COPD Drugs Market: Growth and Forecast 42
5.1 By Value (2013-2017) 43
5.2 By Value (2018-2023) 52
6. Global COPD Drugs Market: Segmental Analysis 53
3

4. (c) AZOTH Analytics
Table of Content
S.No Particulars Page No.
6.1 Global COPD Drugs Market Size, By Drug Type: Breakdown (%) 54
6.1.1 Global COPD Drugs Market Size, By Drug Type, 2017 (%) 54
6.1.2 Global COPD Drugs Market Size, By Drug Type, 2023 (%) 55
6.2 Global Combination Therapy COPD Drugs Market Size, By Value (2013-2023) 56
6.3
Global Anticholinergics COPD Drugs Market Size, By Value (2013-2023)
57
6.4 Global Beta- Agonist COPD Drugs Market Size, By Value (2013-2023) 58
6.5 Global ICS COPD Drugs Market Size, By Value (2013-2023) 59
6.6 Global Other COPD Drugs Market Size, By Value (2013-2023) 60
6.6 Global COPD Drugs: Market Attractiveness, By Drug Type 61
4

5. (c) AZOTH Analytics
Table of Content
S.No Particulars Page No.
7. Global COPD Drugs Market: Regional Analysis 62
7.1 Global COPD Drugs Market Size, By Region : Breakdown (%) 63
7.1.1 Global COPD Drugs Market Size, By Region, 2017 (%) 63
7.1.2 Global COPD Drugs Market Size, By Region, 2023 (%) 63
8. North America COPD Drugs Market: Growth and Forecast 64
8.1 North America COPD Drugs Market: Segmental Analysis 63
8.2 North America COPD Drugs Market Size, By Drug Type: Breakdown (%) 63
8.2.1 North America COPD Drugs Market Size, By Drug Type, 2017 (%) 63
8.2.2 North America COPD Drugs Market Size, By Drug Type, 2023 (%) 63
8.3 North America Combination Therapy COPD Drugs Market Size, By Value (2013-2023) 72
8.4 North America Anticholinergics COPD Drugs Market Size, By Value (2013-2023) 72
8.5 North America Beta- Agonist COPD Drugs Market Size, By Value (2013-2023) 72
8.6 North America ICS COPD Drugs Market Size, By Value (2013-2023) 72
8.7 North America Other COPD Drugs Market Size, By Value (2013-2023) 72
5

6. (c) AZOTH Analytics
Table of Content
S.No Particulars Page No.
8.9 North America COPD Drugs Market: Country Analysis (U.S and Canada) 73
8.9.1 U.S COPD Drugs Market, By Value (2013-2023) 76
8.9.2 U.S COPD Drugs Market, By Drug Type, By Value (2013-2023) 82
8.9.3 Canada COPD Drugs Market, By Value (2013-2023) 84
8.9.4 Canada COPD Drugs Market, By Drug Type, By Value (2013-2023) 90
9. Europe COPD Drugs Market: Growth and Forecast 91
9.1 Europe COPD Drugs Market: Segmental Analysis 92
9.2 Europe COPD Drugs Market Size, By Drug Type: Breakdown (%) 98
9.1.2 Europe COPD Drugs Market Size, By Drug Type, 2017 (%) 98
9.1.3 Europe COPD Drugs Market Size, By Drug Type, 2023 (%) 98
9.3 Europe Combination Therapy COPD Drugs Market Size, By Value (2013-2023) 99
9.4 Europe America Anticholinergics COPD Drugs Market Size, By Value (2013-2023) 99
9.5 Europe America Beta- Agonist COPD Drugs Market Size, By Value (2013-2023) 99
9.6 Europe America ICS COPD Drugs Market Size, By Value (2013-2023) 99
9.7 Europe America Other COPD Drugs Market Size, By Value (2013-2023) 99
6

7. (c) AZOTH Analytics
Table of Content
S.No Particulars Page No.
9.8 Europe COPD Drugs Market: Country Analysis (Germany, France, U.K, Italy) 100
9.8.1 Germany COPD Drugs Market, By Value (2013-2023) 103
9.8.2 Germany COPD Drugs Market, By Drug Type, By Value (2013-2023) 108
9.8.4 France COPD Drugs Market, By Value (2013-2023) 110
9.8.5 France COPD Drugs Market, By Drug Type, By Value (2013-2023) 115
9.8.7 UK COPD Drugs Market, By Value (2013-2023) 117
9.8.6 UK COPD Drugs Market, By Drug Type, By Value (2013-2023) 122
9.8.7 Italy COPD Drugs Market, By Value (2013-2023) 124
9.8.8 Italy COPD Drugs Market, By Drug Type, By Value (2013-2023) 129
7

8. (c) AZOTH Analytics
Table of Content
S.No Page No.
10. APAC COPD Drugs Market: Growth and Forecast 131
10.1 APAC COPD Drugs Market: Segmental Analysis 131
10.2 APAC COPD Drugs Market Size, By Drug Type: Breakdown (%) 137
10.2.1 APAC COPD Drugs Market Size, By Drug Type, 2017 (%) 137
10.2.2 APAC COPD Drugs Market Size, By Drug Type, 2023 (%) 137
10.3 APAC Combination Therapy COPD Drugs Market Size, By Value (2013-2023) 138
10.4 APAC Anticholinergics COPD Drugs Market Size, By Value (2013-2023) 138
10.5 APAC Beta- Agonist COPD Drugs Market Size, By Value (2013-2023) 138
10.6 APAC ICS COPD Drugs Market Size, By Value (2013-2023) 138
10.7 APAC Other COPD Drugs Market Size, By Value (2013-2023) 138
8

9. (c) AZOTH Analytics
Table of Content
S.No Particulars Page No.
10.8 APAC COPD Drugs Market: Country Analysis (China, Japan, and India) 139
10.8.1 China COPD Drugs Market, By Value (2013-2023) 142
10.8.2 China COPD Drugs Market, By Drug Type, By Value (2013-2023) 148
10.8.3 Japan COPD Drugs Market, By Value (2013-2023) 150
10.8.4 Japan COPD Drugs Market, By Drug Type, By Value (2013-2023) 155
10.8.5 India COPD Drugs Market, By Value (2013-2023) 157
10.8.6 India COPD Drugs Market, By Drug Type, By Value (2013-2023) 163
11. ROW COPD Drugs Market: Growth and Forecast 165
11.1 ROW COPD Drugs Market: Segmental Analysis 170
11.2 ROW COPD Drugs Market Size, By Drug Type: Breakdown (%) 171
11.1.1 ROW COPD Drugs Market Size, By Drug Type, 2017 (%) 171
11.1.2 ROW COPD Drugs Market Size, By Drug Type, 2023 (%) 171
9

10. (c) AZOTH Analytics
Table of Content
S.No Page No.
11.3 ROW Combination Therapy COPD Drugs Market Size, By Value (2013-2023) 172
11.4 ROW Anticholinergics COPD Drugs Market Size, By Value (2013-2023) 172
11.5 ROW Beta- Agonist COPD Drugs Market Size, By Value (2013-2023) 172
11.6 ROW ICS COPD Drugs Market Size, By Value (2013-2023) 172
11.7 ROW Other COPD Drugs Market Size, By Value (2013-2023) 172
13. Global COPD Drugs Market: Pipeline Analysis 179
14. Global COPD Drugs Market: Market Dynamics 207
14.1 Global COPD Drugs Market: Drivers 208
14.2 Global COPD Drugs Market: Restrains 212
14.3 Global COPD Drugs Market: Trends 214
14.4 Global COPD Drugs Market: Product Benchmarking 219
14.5 Global COPD Drugs Market: Sales Analysis, By Company 221
10

11. (c) AZOTH Analytics
Table of Content
S.No Particulars Page No.
15. Porter Five Force Analysis 232
16. SWOT Analysis 233
17. Company Profiles 234
17.1 GSK
235
17.2 AstraZeneca
238
17.3 Boehringer-Ingelheim
240
17.4 Teva Pharmaceuticals
242
17.5 Chiesi Farmaceutici S.p.A.
244
17.6 Novartis
246
17.7 Cipla
248
17.8 Mylan
250
17.9 Vectura Group Plc,
252
17.10 Sunovion
254
18. About Us 255
11

12. (c) AZOTH Analytics
List of Figures
Figure No. Figure Title Page No.
Figure 1: Management of COPD 36
Figure 2: Global COPD Drugs Market Size, By Value, 2013-2017 (USD Million) 43
Figure 3: Smoking Prevalence Among Adults, By Gender, 2015 44
Figure 4: Cigarette Sales Share, By Region, 2017 (% of total) 44
Figure 5: Deaths Due To Air Pollution, By Disease Type, 2016 45
Figure 6: Percentage of NCD Cases Due to Air Pollution, 2016 45
Figure 7: Global PM2.5 air pollution, mean annual exposure, 2012-2016 45
Figure 8: Global Aged Population(Above 65), By Country, 2017 (% of total) 46
Figure 9: Global Aged Population (Above 65), 2013-2017 (% of total) 46
Figure 10: Global Overweight Population (Age above 18), 2013-2016 (% of total) 47
Figure 11: Global Overweight Population (Age above 18), By Sex, 2016 (% of total) 47
Figure 12: COPD Facts and Figures 47
Figure 13: Generic Market Value Share, In 2006 (Left) &2016 (Right), By Region 48
Figure 14: Healthcare Expenditure (Share of GDP), By Selected Country, 2013-2017 (In %) 49
Figure 15: Expected Global Medical Spending in 2020, By Product Type, (% of Total) 49
Figure 16: Expected Global Medical Spending in 2020, By Region, (% of Total) 49
Figure 17: COPD DAYLs Per 100000, By Country, All Sex, All Age,2017 50
Figure 18: GDP Per Capita PPP, By Region, 2018 (in Thousand USD) 50
Figure 19: Global Expected Healthcare Industry Outlook 51
Figure 20: Regional Expected Healthcare Industry Growth Rate By Year 2020 51
12

13. (c) AZOTH Analytics
List of Figures
Figure No. Figure Title Page No.
Figure 21: Regional Expected Healthcare Industry Growth Rate By Year 2020 52
Figure 22: Global COPD Drugs Market Size, By Drug Type, 2017 (%) 54
Figure 23: Global COPD Drugs Market Size, By Drug Type, 2023F (%) 55
Figure 24: Global Combination Therapy COPD Drugs Market, By Value, 2013-2017 (USD Million) 56
Figure 25: Global Combination Therapy COPD Drugs Market, By Value, 2018-2023(USD Million) 56
Figure 26: Global Anticholinergics COPD Drugs Market, By Value, 2013-2017 (USD Million) 57
Figure 27: Global Anticholinergics COPD Drugs Market, 2018-2023(USD Million) 57
Figure 28: Global Beta-Agonist COPD Drugs Market, By Value, 2013-2017 (USD Million) 58
Figure 29: Global Beta-Agonist COPD Drugs Market, By Value, 2018-2023(USD Million) 58
Figure 30: Global ICS COPD Drugs Market, By Value, 2013-2017 (USD Million) 59
Figure 31: Global ICS COPD Drugs Market, By Value, 2018-2023(USD Million) 59
Figure 32: Global Other COPD Drugs Market, By Value, 2013-2017 (USD Million) 60
Figure 33: Global Other COPD Drugs Market, By Value, 2018-2023(USD Million) 60
Figure 34: Global Market Attractiveness, By Product Type, 2023F 61
Figure 35: Global COPD Drugs Market Size, By Region, 2017 (%) 63
Figure 36: Global COPD Drugs Market Size, By Region, 2023F (%) 63
Figure 37: North America COPD Drugs Market, By Value, 2013-2017 (USD Million) 65
Figure 38: United States Spending on Medicines, 2013-2017 (In USD Billion) 67
Figure 39: Patented and Non-Patented Drugs Sales in Canada, 2013-2016 (USD Billion) 67
Figure 40: North America, Smoking Prevalence, Age 15+, 2013-2016 68
13

14. (c) AZOTH Analytics
List of Figures
Figure No. Figure Title Page No.
Figure 41: North America, Smoking Prevalence, Age 15+, 2013-2016 68
Figure 42: United States health care expenditure per capita,2013-2016(USD) 68
Figure 43: Canada health care expenditure per capita,2013-2016(USD) 68
Figure 44: North America population aged 65 and above, 2013-2017 (% of total) 69
Figure 45: North America Healthcare Cost Per Capita, 2017 (USD) 69
Figure 46: North America GDP per Capita, 2013-2017 (USD) 69
Figure 47: North America COPD Drugs Market, By Value, 2018-2023 (USD Million) 70
Figure 48: North America COPD Drugs Market Size, By Drug Type, 2017 (%) 71
Figure 49: North America COPD Drugs Market Size, By Drug Type, 2023F (%) 71
Figure 50: North America COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million) 72
Figure 51: North America COPD Drugs Market, By Drug Type , By Value, 2018-2023(USD Million) 72
Figure 52: North America COPD Drugs Market Size, By Countries, 2017 (%) 74
Figure 53: North America COPD Drugs Market Size, By Countries, 2023F (%) 74
Figure 54: USA COPD Drugs Market, By Value, 2013-2017 (USD Million) 76
Figure 55: USA COPD Drugs Market, By Value, 2018-2023(USD Million) 76
Figure 56: Smoking Prevalence, Age 15+, 2012-2016 78
Figure 57: Canada, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016 78
Figure 58: United States Per Capita Spending on Medicines, 2013-2017 (In USD) 79
Figure 59: Pharmacy & Drug Store Sales in United States, 2013-2016 (In USD Billion) 79
Figure 60: Medical and Healthcare Research & Development Spending, 2013-2016 (In USD Million) 79

15. (c) AZOTH Analytics
List of Figures
Figure No. Figure Title Page No.
Figure 61: U.S., Population ages 65 and above, 2013-2017 (% of total) 80
Figure 62: U.S., Population ages 65 and above, Forecast (In Millions) 80
Figure 63: U.S., Per Capita Expenditure on Healthcare, 2012-2018E (In USD) 80
Figure 64: U.S., GDP (Current USD), 2013-2017 (In USD Trillion) 80
Figure 65: USA COPD Drugs Market Size, By Drug Type, 2017 (%) 81
Figure 66: USA COPD Drugs Market Size, By Drug Type, 2023F (%) 81
Figure 67: USA COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million) 82
Figure 68: USA COPD Drugs Market, By Drug Type, By Value, 2018-2023(USD Million) 82
Figure 69: Canada COPD Drugs Market, By Value, 2013-2017 (USD Million) 84
Figure 70: Canada COPD Drugs Market, By Value, 2018-2023(USD Million) 84
Figure 71: Percentage Change in Deaths Between, 2007–2017 Due to Respiratory Diseases 85
Figure 72: Canada, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016 86
Figure 73: Canada, Smoking Prevalence, Age 15+, 2012-2016 86
Figure 74: Number of Retail Pharmacies in Canada, 2013-2017 87
Figure 75: Number of Hospitals Establishments in Canada, By Province, 2015 87
Figure 76: Canada, Expenditure on Health as a share of GDP, 2012-2017 (in %) 88
Figure 77: Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD) 88
Figure 78: Canada, Population ages 65 and above, 2012-2017 (% of total) 88
Figure 79: Canada COPD Drugs Market Size, By Drug Type, 2017 (%) 89
Figure 80: Canada COPD Drugs Market Size, By Drug Type, 2023F (%) 89

16. (c) AZOTH Analytics
List of Figures
Figure No. Figure Title Page No.
Figure 81: Canada COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million) 90
Figure 82: Europe COPD Drugs Market, By Value, 2013-2017 (USD Million) 92
Figure 83: Europe Health Expenditure, By Select Country, 2016 (% of GDP) 94
Figure 84: Europe Population ages 65 years and above (% of total population), 2013-17 94
Figure 85: European Union, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016 95
Figure 86: European Union, Smoking Prevalence, Age 15+, 2012-2016 95
Figure 87: Cause of Death, EU-28, 2015, Per 1000000 inhabitants, Both Sex 96
Figure 88: Europe, COPD Prevalence, By Selected Countries, 2017, (In Million) 96
Figure 89: Mean Average Age At Which Majority of Population Affected By COPD, By Region 96
Figure 90: Europe COPD Drugs Market, By Value, 2018-2023 (USD Million) 97
Figure 91: Europe COPD Drugs Market Size, By Drug Type, 2017 (%) 98
Figure 92: Europe COPD Drugs Market Size, By Drug Type, 2023F (%) 98
Figure 93: Europe COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million) 99
Figure 94: Europe COPD Drugs Market Size, By Countries, 2017 (%) 101
Figure 95: Europe COPD Drugs Market Size, By Countries, 2023F (%) 101
Figure 96: Germany COPD Drugs Market, By Value, 2013-2017 (USD Million) 103
Figure 97: Germany COPD Drugs Market, By Value, 2018-2023(USD Million) 103
Figure 98: Germany COPD Prevalence, 2013-2017, 2018E-20123E, (in Millions) 104
Figure 99: PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016 105
Figure 100: Germany, Population ages 65 and above, 2012-2017 (% total) 105
16

17. (c) AZOTH Analytics
List of Figures
Figure No. Figure Title Page No.
Figure 101: Germany, Spending on Healthcare, 2015 & 2040E, (USD Per Person) 105
Figure 102: Germany, Healthcare Related Statistics, 2017 105
Figure 103: Germany, Smoking Prevalence, Age 15+, 2012-2016, (% of Total) 106
Figure 104: Germany, Percentage Change In Cause of Death Between 2007-2017 106
Figure 105: Germany COPD Drugs Market Size, By Drug Type, 2017 (%) 107
Figure 106: Germany COPD Drugs Market Size, By Drug Type, 2023F (%) 107
Figure 107: Germany COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million) 108
Figure 108: France COPD Drugs Market, By Value, 2013-2017 (USD Million) 110
Figure 109: France COPD Drugs Market, By Value, 2018-2023(USD Million) 110
Figure 110: France, COPD Prevalence, 2013-2017, 2018E-20123E, (in Millions) 111
Figure 111: France, Smoking Prevalence, Age 15+, 2012-2017, (% of Total) 112
Figure 112: France, Healthcare Infrastructure Related Statistics 112
Figure 113: France, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2017 112
Figure 114: France, Health Expenditure, (% of GDP), 2012-2015 (USD) 113
Figure 115: France, Population Ages 65 and Above (% of total), 2012-2017 113
Figure 116: France, Cause of Death, 2017, (% of Total) 113
Figure 117: France, Spending on Healthcare, 2015 & 2040, (USD Per Person) 113
Figure 118: France COPD Drugs Market Size, By Drug Type, 2017 (%) 114
Figure 119: France COPD Drugs Market Size, By Drug Type, 2023F (%) 114
Figure 120: France COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million) 115
17

18. (c) AZOTH Analytics
List of Figures
Figure No. Figure Title Page No.
Figure 121: U.K COPD Drugs Market, By Value, 2013-2017 (USD Million) 117
Figure 122: U.K COPD Drugs Market, By Value, 2018-2023(USD Million) 117
Figure 123: Germany, COPD Prevalence, 2013-2017, 2018E-20123E, (in Millions) 118
Figure 124: U.K, Health Expenditure, (% of GDP), 2013-2017 (USD) 119
Figure 125: U.K, Population Ages 65 and Above (% of total), 2012-2017 119
Figure 126: U.K, Population Ages 65 and Above (% of total), 2012-2017 119
Figure 127: U.K, Spending on Healthcare, 2015 & 2040, (USD Per Person) 119
Figure 128: UK, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2017 120
Figure 129: UK, Smoking Prevalence (% of Total), 2012-2017 120
Figure 130: U.K COPD Drugs Market Size, By Drug Type, 2017 (%) 121
Figure 131: U.K COPD Drugs Market Size, By Drug Type, 2023F (%) 121
Figure 132: U.K COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million) 122
Figure 133: Italy COPD Drugs Market, By Value, 2013-2017 (USD Million) 124
Figure 134: Italy COPD Drugs Market, By Value, 2018-2023(USD Million) 124
Figure 135: Germany, COPD Prevalence, 2013-2017, 2018E-2023E, (in Millions) 125
Figure 136: Italy, Health Expenditure, (% of GDP), 2013-2017 (USD) 126
Figure 137: Italy, Population Ages 65 and Above (% of total), 2012-2017 126
Figure 138: Italy, Healthcare Infrastructure Related Statistics 126
Figure 139: Italy, Spending on Healthcare, 2015 & 2040, (USD Per Person) 126
Figure 140: Italy, Smoking Prevalence, Age 15+, 2012-2016 127
18

19. (c) AZOTH Analytics
List of Figures
Figure No. Figure Title Page No.
Figure 141: Italy, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter) 2012-2016 127
Figure 142: Italy COPD Drugs Market Size, By Drug Type, 2017 (%) 128
Figure 143: Italy COPD Drugs Market Size, By Drug Type, 2023F (%) 128
Figure 144: Italy COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million) 129
Figure 145: APAC COPD Drugs Market, By Value, 2013-2017 (USD Million) 131
Figure 146: GDP Per Capita in APAC, By Select Country, 2016 (In USD) 133
Figure 147: Population ages 65 and above, By Select Country, 2017 (% of total) 133
Figure 148: Men Smoking Prevalence in Asia, 2016, (% of Total Population) 133
Figure 149: East Asia & Pacific, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016 134
Figure 150: South Asia, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016 134
Figure 151: China, Pharmaceuticals Industry Revenue (USD Billion) 135
Figure 152: Japan, Total Drugs Market, 2013-2017, USD Billion 135
Figure 153: India Pharma Market, 2015-2017, (USD Billion) 135
Figure 154: APAC COPD Drugs Market, By Value, 2018-2023 (USD Million) 136
Figure 155: APAC COPD Drugs Market Size, By Drug Type, 2017 (%) 137
Figure 156: APAC COPD Drugs Market Size, By Drug Type, 2023F (%) 137
Figure 157: APAC COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million) 138
Figure 158: APAC COPD Drugs Market Size, By Countries, 2017 (%) 140
Figure 159: APAC COPD Drugs Market Size, By Countries, 2023F (%) 140
Figure 160: China COPD Drugs Market, By Value, 2013-2017 (USD Million) 142
19

20. (c) AZOTH Analytics
List of Figures
Figure No. Figure Title Page No.
Figure 161: China COPD Drugs Market, By Value, 2018-2023(USD Million) 142
Figure 162: China, Smoking Prevalence, Age 15+, % of Total Population, 2012-2016 144
Figure 163: China, Tobacco Attributable Deaths, 2030 144
Figure 164: China, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016 144
Figure 165: Beijing annual PM2.5 air pollution levels, 2013-2017, ( in micrograms per cubic meter of air) 145
Figure 166: China Co2 Emissions, 2013-2016 (Billion Metric Tons) 145
Figure 167: China, Population Above 65 (% of Total), 2013-2017 145
Figure 168: China, GDP Growth Per Year, 2015-2019 (In %) 146
Figure 169: China, Share of Urban Population, 2012-2017 (In %) 146
Figure 170: China, Total Population, 2013-2021F (In Billion) 146
Figure 171: China COPD Drugs Market Size, By Drug Type, 2017 (%) 147
Figure 172: China COPD Drugs Market Size, By Drug Type, 2023F (%) 147
Figure 173: China COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million) 148
Figure 174: Japan COPD Drugs Market, By Value, 2013-2017 (USD Million) 150
Figure 175: Japan COPD Drugs Market, By Value, 2018-2023(USD Million) 150
Figure 176: Japan, Population ages 65 and above, 2012-2017 (% of total) 151
Figure 177: Japan, Smoking Prevalence, Age 15+, 2012-2016, (% of Total Prevalence) 152
Figure 178: Japan, Medical Facilities Outlook 152
Figure 179: Japan Healthcare Expenditure Outlook (%) 152
Figure 180: Japan, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016 153
20

21. (c) AZOTH Analytics
List of Figures
Figure No. Figure Title Page No.
Figure 181: Japan, GDP Growth Per Year, 2015-2019F (In %) 153
Figure 182: Japan COPD Drugs Market Size, By Drug Type, 2017 (%) 154
Figure 183: Japan COPD Drugs Market Size, By Drug Type, 2023F (%) 154
Figure 184: Japan COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million) 155
Figure 185: India COPD Drugs Market, By Value, 2013-2017 (USD Million) 157
Figure 186: India COPD Drugs Market, By Value, 2018-2023(USD Million) 157
Figure 187: India, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2017 159
Figure 188: India, Smoking Prevalence, Age 15+, 2012-2016, (% of Total) 160
Figure 189: India, Diseases & Medical Industry Outlook 160
Figure 190: India, Population ages 65 and above, 2013-2017 161
Figure 191: India, Total Population, 2013-2023F (In Billion) 161
Figure 192: Pharma Export From India Market, 2013-2017, (USD Billion) 161
Figure 193: India COPD Drugs Market Size, By Drug Type, 2017 (%) 162
Figure 194: India COPD Drugs Market Size, By Drug Type, 2023F (%) 162
Figure 195: India COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million) 163
Figure 196: ROW COPD Drugs Market, By Value, 2013-2017 (USD Million) 165
Figure 197: South Africa, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2013-2016 167
Figure 198: South Africa, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2013-2016 167
Figure 199: GDP Per Capita in ROW, By Select Country, 2013 (In USD) 168
Figure 200: GDP Per Capita in ROW, By Select Country, 2013 (In USD) 168
21

22. (c) AZOTH Analytics
List of Figures
Figure No. Figure Title Page No.
Figure 201: GDP Per Capita in ROW, By Select Country, 2013 (In USD) 169
Figure 202: Middle East and North Africa, Population ages 65 and above (% of total) 169
Figure 203: ROW COPD Drugs Market, By Value, 2018-2023 (USD Million) 170
Figure 204: ROW COPD Drugs Market Size, By Drug Type, 2017 (%) 171
Figure 205: ROW COPD Drugs Market Size, By Drug Type, 2023F (%) 171
Figure 206: ROW COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million) 172
Figure 207: Exacerbation During the Study Over a Period of 12 Months (Part B) 198
Figure 208: Percentage aged 60 years and over, (2000, 2015, 2030,2050) 211
Figure 209: COPD - Major Drugs Sales, By Drug Type, 2017 (USD Million) 220
Figure 210: GSK COPD Drugs Sales, 2018-2023 Estimated, USD Million 223
Figure 211: AstraZeneca COPD Drugs Sales, 2018-2023 Estimated, USD Million 226
Figure 212: Novartis COPD Drugs Sales, 2018-2023 Estimated, USD Million 229
Figure 213: COPD - Major Drugs Sales, By Drug Type, 2017 (USD Million) 233
Figure 214: GSK, Revenues, 2013-2017 (USD Million) 236
Figure 215: GSK, Revenues, 2013-2017 (USD Million) 236
Figure 216: GSK, Revenue, By Segments, 2017(%) 236
Figure 217: GSK, Revenue, By Pharmaceuticals Segment, 2017 (USD Million) 236
Figure 218: GSK COPD Drugs Patent Expiry Details 237
Figure 219: GSK, Respiratory Segment Expected Revenue By 2023 (USD Million) 237
Figure 220: AstraZeneca, Net Sales, 2013-2017 (USD Million) 239
22

23. (c) AZOTH Analytics
List of Figures
Figure No. Figure Title Page No.
Figure 221: AstraZeneca Revenue, By Segments, 2017(%) 239
Figure 222: AstraZeneca Revenue, By Region, 2017(%) 239
Figure 223: Boehringer-Ingelheim, Net Sales, 2013-2017 (USD Million) 241
Figure 224: Boehringer-Ingelheim, By Segments, 2017(%) 241
Figure 225: Boehringer-Ingelheim, By Region, 2017(%) 241
Figure 226: Teva Pharmaceuticals, Net Sales, 2013-2017 (USD Million) 243
Figure 227: Teva Pharmaceuticals, By Segments, 2017(%) 243
Figure 228: Teva Pharmaceuticals, By Region, 2017(%) 243
Figure 229: Chiesi Farmaceutici S.p.A. , Net Sales, 2013-2017 (USD Million) 245
Figure 230: Chiesi Farmaceutici S.p.A. , By Segments, 2017(%) 245
Figure 231: Chiesi Farmaceutici S.p.A. , By Segments, 2017(%) 245
Figure 232: Novartis, Net Sales, 2013-2017 (USD Million) 247
Figure 233: Novartis, Revenue, By Segment, 2017(%) 247
Figure 234: Novartis, Revenue, By Region, 2017(%) 247
Figure 235: Cipla, Net Sales, 2013-2017 (USD Million) 249
Figure 236: Cipla , By Region, 2017(%) 249
Figure 237: Mylan, Net Sales, 2013-2017 (USD Million) 251
Figure 238: Mylan, By Region, 2017(%) 251
Figure 239: Vectura Group , Net Sales, 2013-2017 (USD Million) 253
Figure 240: Vectura Group, By Products, 2017(%) 253
23

24. (c) AZOTH Analytics
List of Figures
Figure No. Figure Title Page No.
Table A: Stages of COPD 35
Table B: Beta-2 Agonist Drugs For in COPD Treatment 37
Table C: Anti-muscarinic Drugs For COPD Treatment 38
Table D: Combination Bronchodilators Therapy For COPD Treatment 39
Table E: ICS Combination Therapy For COPD Treatment 40
Table F: EU-5 Socio-Economical Statistics, 2017 94
Table G: PT010 Clinical Trails 176
Table H: Other PT010 Phase-3 Trails 179
Table I: Primary endpoint results assessed by FEV1 180
Table J: Duaklir Clinical Trails 184
Table K: Statistical Analysis 188
Table L: Statistical Analysis 188
Table M: Statistical Analysis 189
Table N: Statistical Analysis 189
Table O: Statistical Analysis 190
Table P: Statistical Analysis 190
Table Q: Statistical Analysis 190
Table R: Statistical Analysis 191
Table S: Statistical Analysis 191
Table T: Danirixin Clinical Studies 195
24

25. (c) AZOTH Analytics
List of Figures
Figure No. Figure Title Page No.
Table U: Nemiralisib Clinical Studies 203
Table V: GSK2269557 Clinical Studies 204
Table W: Other Major Drugs In Development Pipeline 206
Table X: Product Benchmarking, By Drug Type 219
Table Y: GSK COPD Drugs Sales, 2017, USD Million 222
Table Z: AstraZeneca COPD Drugs Sales, 2017, USD Million 225
Table AB: Novartis COPD Drugs Sales, 2017, USD Million 228
Table AC: Boehringer Ingelheim COPD Drugs Sales, 2017, USD Million 230
Table AD: Product Benchmarking, By Drug Type 232
25

26. (c) AZOTH Analytics
Research Methodology
For our study on COPD Drugs Market, we have conducted comprehensive secondary research followed by an
extensive primary research. In the process of secondary research, we have scrutinized industry documents,
accessed from open sources, premium paid databases (Bloomberg, Thomson Reuters, Factiva) and our internal
knowledge base. In the process of primary research, we have interviewed various industry experts across the
value chain of COPD Drugs Market.
Market size of the actual period (2013-2017) has been evaluated on the basis of growth trends of the industry
in the last five years, and confirming the findings through primary research. Annual reports of the companies
are scanned to further validate the market size and to estimate the size of various other end-user sectors.
Market sizing and growth in the forecast period (2018-2023) is estimated through product mapping,
application in end-user industries, growth of allied sectors and historical growth pattern of the industry. All the
relevant data points/ statistics in the forecast period are validated through relevant and reliable primary
sources.
Report Focus: COPD Drugs Market:
-By Drug Type (Combination Therapy Drugs, Anticholinergics, Beta-Agonist, Inhaled Corticosteroids, Others)
-By Region (North America, Europe, APAC, and ROW)
-By Country (U.S, Canada, Germany, France, U.K., Italy, Japan, China, India)
-Pipeline Analysis (PT010, Duaklir, Nemiralisib, Danirixin)
26

27. (c) AZOTH Analytics
Executive Summary
Market Drivers & Challenges
• Drivers
 Rising Pollution Level and Smoking
Prevalence.
 Increased Awareness.
 Increasing Geriatric Population.
• Challenges
 Low Awareness
Trends
Global COPD Drugs market is
anticipated to advance at a high CAGR
of 2.47 % during 2018-2023, mainly
due to the rising smoking prevalence,
growing geriatric population, and
increasing pollution level.
 Once-Daily Triple Combination
Therapy.
 Stem Cell Therapy For COPD.
Competitive Landscape
Glaxo SmithKline, AstraZeneca, Boehringer-Ingelheim, TEVA Pharmaceuticals, Chiesi
Pharmaceuticals, Novartis, Merck, Cipla, Mylan, Vectura, and Sunovion.
27

28. (c) AZOTH Analytics
Global COPD Drugs Market
Source: Azoth Analytics Estimates
Xx
Xx
Xx
Xx
Xx
Xx
CAGR: 2013-2017
xx%
2013 2014 2015 2016 2017
Figure 2: Global COPD Drugs Market Size, By Value, 2013-2017 (USD Million)
Rapid rise in COPD prevalence, especially in lower and middle income countries has impelled the market
growth in actual period.
28

29. (c) AZOTH Analytics
Global COPD Drugs Market
Source: Azoth Analytics Estimates
CAGR: 2018-2023
xx%
2018 2019 2020 2021 2022 2023
Figure 21: Global COPD Drugs Market Size, By Value, Forecast, 2018-2023 (USD Million)
Xx
Xx
Xx
Xx
Xx
New drug launches and rapidly increasing pollution level coupled with rising geriatric population are
anticipated to drive the market growth in forecast period.
29

30. (c) AZOTH Analytics
Global COPD Drugs Market- Segment Analysis
30

31. (c) AZOTH Analytics
Global Insulin Pumps Market, By Value
Figure 24: Global Combination Therapy COPD Drugs
Market, By Value, 2013-2017 (USD Million)
Source: Azoth Analytics Estimates
CAGR 2013-2017
xx%
CAGR 2018-2023
xx%
Figure 25: Global Combination Therapy COPD Drugs
Market, By Value, 2018-2023(USD Million)
Global Combination Therapy COPD Drugs Market
Xx
Xx
Xx
Xx
Xx
Xx
Xx
Xx
Xx
Xx
Xx
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
31

32. (c) AZOTH Analytics
Global Insulin Pumps Market, By Value
Figure 26: Global Anticholinergics COPD Drugs
Market, By Value, 2013-2017 (USD Million)
Source: Azoth Analytics Estimates
Figure 27: Global Anticholinergics COPD Drugs
Market, 2018-2023(USD Million)
Global Anticholinergics COPD Drugs Market
32
CAGR 2013-2017
xx%
CAGR 2018-2023
xx%
Xx
Xx
Xx
Xx
Xx
Xx
Xx
Xx
Xx
Xx
Xx
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

33. (c) AZOTH Analytics
Global Insulin Pumps Market, By Value
Figure 28: Global Beta-Agonist COPD Drugs Market,
By Value, 2013-2017 (USD Million)
Source: Azoth Analytics Estimates
Figure 29: Global Beta-Agonist COPD Drugs Market,
By Value, 2018-2023(USD Million)
Global Beta-Agonist COPD Drugs Market
33
CAGR 2013-2017
xx%
CAGR 2018-2023
xx%
Xx
Xx
Xx
Xx
Xx
Xx
Xx
Xx
Xx
Xx
Xx
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

34. (c) AZOTH Analytics
Global Insulin Pumps Market, By Value
Figure 30: Global ICS COPD Drugs Market, By Value,
2013-2017 (USD Million)
Source: Azoth Analytics Estimates
Figure 31: Global ICS COPD Drugs Market, By Value,
2018-2023(USD Million)
Global ICS COPD Drugs Market
34
CAGR 2013-2017
xx%
CAGR 2018-2023
xx%
Xx
Xx
Xx
Xx
Xx
Xx
Xx
Xx
Xx
Xx
Xx
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

35. (c) AZOTH Analytics
Global Insulin Pumps Market, By Value
Figure 32: Global Other COPD Drugs Market, By
Value, 2013-2017 (USD Million)
Source: Azoth Analytics Estimates
Figure 33: Global Other COPD Drugs Market, By
Value, 2018-2023(USD Million)
Global Others COPD Drugs Market
35
CAGR 2013-2017
xx%
CAGR 2018-2023
xx%
Xx
Xx
Xx
Xx
Xx
Xx
Xx
Xx
Xx
Xx
Xx
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

36. (c) AZOTH Analytics
Global COPD Drugs Market- Market Attractiveness
Source: Azoth Analytics Estimates
Figure 34: Global Market Attractiveness, By Product Type, 2023F
Combination Therapy
Anticholinergics
Beta-Agonist
0.00%
1.00%
2.00%
3.00%
4.00%
5.00%
6.00%
CompoundAnnualGrowthRate
Market Size (USD Million)
Others
ICS
Xx
Xx
Xx
Xx
Xx
Xx
Xx
36

37. (c) AZOTH Analytics
North America COPD Drugs Market
Source: Azoth Analytics Estimates
Figure 37: North America COPD Drugs Market, By Value, 2013-2017 (USD Million)
Presence of enormous patient base, ageing population coupled with increasing out of pocket-healthcare
expenditure impelled the growth of COPD Drugs.
37
Xx
Xx
Xx
Xx
Xx
Xx
CAGR: 2013-2017
xx%
2013 2014 2015 2016 2017

38. (c) AZOTH Analytics
North America Insulin Pumps Market, By Value
Figure 50: North America COPD Drugs Market,
By Drug Type, By Value, 2013-2017 (USD Million)
Source: Azoth Analytics Estimates
Figure 51: North America COPD Drugs Market,
By Drug Type , By Value, 2018-2023(USD Million)
North America COPD Drugs Market: By Drug Type
38
CAGR 2013-2017
Combination Therapy: xx%
Anticholinergics: xx%
Beta- Agonist: xx%
Others: xx%
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Combination Therapy 2534.16 2678.31 2826.77 2979.55 3136.68 3284.53 3435.65 3590.01 3747.62 3907.86 4072.56
Anti-Cholinergics 1448.09 1433.95 1416.09 1394.46 1369.05 1338.86 1305.23 1268.16 1227.65 1183.62 1136.37
Beta- Agaonist 337.89 349.39 360.97 372.63 384.36 394.69 405.02 415.34 425.67 436.20 446.32
Others 506.83 524.27 541.84 559.54 577.36 593.63 609.92 626.26 642.63 659.56 675.49
CAGR 2018-2023
Combination Therapy: xx%
Anticholinergics: xx%
Beta- Agonist: xx%
Others: xx%
Xx
Xx
Xx
Xx
Xx
Xx
Xx

39. (c) AZOTH Analytics
USA COPD Drugs Market
39

40. (c) AZOTH Analytics
Global Insulin Pumps Market, By Value
Figure 54: USA COPD Drugs Market, By Value, 2013-
2017 (USD Million)
Source: Azoth Analytics Estimates
Figure 55: USA COPD Drugs Market, By Value,
2018-2023(USD Million)
USA COPD Drugs Market
40
CAGR 2013-2017
xx%
CAGR 2018-2023
xx%
Xx
Xx
Xx
Xx
Xx
Xx
Xx
Xx
Xx
Xx
Xx
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

41. (c) AZOTH Analytics
USA Insulin Pumps Market, By Value
Figure 67: USA COPD Drugs Market,
By Drug Type, By Value, 2013-2017 (USD Million)
Source: Azoth Analytics Estimates
CAGR 2013-2017
Combination Therapy: xx%
Anticholinergics: xx%
Beta- Agonist: xx%
Others: xx%
Figure 68: USA COPD Drugs Market,
By Drug Type, By Value, 2018-2023(USD Million)
USA COPD Drugs Market, By Drug Class
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Combination Therapy 2534.16 2678.31 2826.77 2979.55 3136.68 3284.53 3435.65 3590.01 3747.62 3907.86 4072.56
Anti-Cholinergics 1448.09 1433.95 1416.09 1394.46 1369.05 1338.86 1305.23 1268.16 1227.65 1183.62 1136.37
Beta- Agaonist 337.89 349.39 360.97 372.63 384.36 394.69 405.02 415.34 425.67 436.20 446.32
Others 506.83 524.27 541.84 559.54 577.36 593.63 609.92 626.26 642.63 659.56 675.49
CAGR 2018-2023
Combination Therapy: xx%
Anticholinergics: xx%
Beta- Agonist: xx%
Others: xx%
Xx
Xx
Xx
Xx
Xx
Xx
Xx
41

42. About Azoth Analytics Pvt Ltd.
Azoth Analytics (ISO 9001:2015) is a business research and analytics company that creates in-depth research reports and provides customized research
solutions and consulting services. An ISO 9001:2015 certified company, Azoth Analytics adheres to international quality management standard and has strong
commitment to a culture of continuous improvement. The business research and market analysis of Azoth Analytics helps organizations across different
industry verticals solve their business problems. Strategic market sizing and data dredging techniques include secondary research, and primary research
(interviews with management personnel and industry experts). Azoth Analytics provide syndicated and customized market research reports on different
verticals including pharmaceutical and healthcare, oil and gas and power, chemicals, automotive, technology, FMCG, food & beverages and media sectors.
42